Singapore markets closed

Astria Therapeutics, Inc. (ATXS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.0850+0.0650 (+1.62%)
As of 10:12AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close4.0200
Open4.0500
Bid4.0000 x 1100
Ask4.2000 x 800
Day's range3.9501 - 4.0850
52-week range3.8300 - 15.7200
Volume3,647
Avg. volume19,431
Market cap53.174M
Beta (5Y monthly)1.42
PE ratio (TTM)N/A
EPS (TTM)-24.5760
Earnings date08 Aug 2022 - 12 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est22.80
  • Business Wire

    Astria Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

    BOSTON, May 12, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

  • Business Wire

    Astria Therapeutics to Present STAR-0215 Data at the 2022 Fc Receptor and IgG Targeted Therapies Conference

    BOSTON, April 21, 2022--Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will share new preclinical data for STAR-0215 in a presentation titled "Development of STAR-0215: An Engineered IgG1 Monoclonal Antibody Targeting Plasma Kallikrein for the Prevention of HAE" at the 2022 Fc Receptor a

  • Business Wire

    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, April 04, 2022--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted equity awards on April 1, 2022 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astr